Intermediate for Daclatasvir. Daclatasvir (trade name: Daklinza) is a medication used in combination with other medications to treat hepatitis C (HCV). Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A which is critical for HCV viral transcription and translation. Daclatasvir has been approved by the U.S Food and Drug Administration on June 24, 2015.
Product Name: 4,4'-Bis(2-bromoacetyl)biphenyl
CAS Number: 4072-67-7
Molecular Weight:  396.0776
Molecular Formula:  C16H12Br2O2
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.